R
R. Riese
Researcher at Pfizer
Publications - 44
Citations - 2729
R. Riese is an academic researcher from Pfizer. The author has contributed to research in topics: Tofacitinib & Janus kinase inhibitor. The author has an hindex of 19, co-authored 44 publications receiving 2280 citations.
Papers
More filters
Journal ArticleDOI
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Joel M. Kremer,Zhanguo Li,Stephen B. Hall,Roy Fleischmann,Mark C. Genovese,E. Martin-Mola,John D. Isaacs,David Gruben,Gene V. Wallenstein,Sriram Krishnaswami,Samuel H. Zwillich,Tamas Koncz,R. Riese,John S. Bradley +13 more
TL;DR: Tofacitinib is a novel, oral, Janus kinase inhibitor that treats rheumatoid arthritis (RA) in combination with nonbiologic DMARDs.
Journal ArticleDOI
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley Cohen,Yoshiya Tanaka,Xavier Mariette,Jeffrey R. Curtis,Eun Bong Lee,Peter Nash,Kevin L. Winthrop,Christina Charles-Schoeman,Krishan Thirunavukkarasu,Ryan DeMasi,Jamie Geier,Kenneth Kwok,Lisy Wang,R. Riese,Juergen Wollenhaupt +14 more
TL;DR: An integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA is reported, finding AEs were generally stable over time and no new safety signals were observed compared with previous tofacItinib reports.
Journal ArticleDOI
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop,Hisashi Yamanaka,Hernan Valdez,Eric Mortensen,Robert Chew,Sriram Krishnaswami,Thomas T. Kawabata,R. Riese +7 more
TL;DR: The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.
Journal ArticleDOI
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Jürgen Wollenhaupt,Joel Silverfield,Eun Bong Lee,Jeffrey R. Curtis,Susan P. Wood,Koshika Soma,Chudy I. Nduaka,B. Benda,David Gruben,Hiroyuki Nakamura,Yoshihiro Komuro,Samuel H. Zwillich,Lisy Wang,R. Riese +13 more
TL;DR: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 months in patients with RA, as measured by ACR response rate, DAS28-4-ESR, and HAQ-DI assessments.
Journal ArticleDOI
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Kevin L. Winthrop,Sung Hwan Park,Ahmet Gül,Mario H. Cardiel,Juan J. Gomez-Reino,Yoshiya Tanaka,Kenneth Kwok,Tatjana Lukic,E. Mortensen,D. Ponce de Leon,R. Riese,Hernan Valdez +11 more
TL;DR: Tuberculosis was the most common OI reported but was rare in regions of low and medium TB incidence, and patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.